Fig. 3From: Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a reviewThe screening workflow of PD-1/PD-L1 inhibitors. The identification of PD-1/PD-L1 inhibitors is required by using a series of assays including binding affinity assay, blockage ability assay, cell-based functional assay and xenograft model assayBack to article page